全文获取类型
收费全文 | 15735篇 |
免费 | 3166篇 |
国内免费 | 69篇 |
专业分类
耳鼻咽喉 | 245篇 |
儿科学 | 529篇 |
妇产科学 | 426篇 |
基础医学 | 1579篇 |
口腔科学 | 149篇 |
临床医学 | 2272篇 |
内科学 | 3639篇 |
皮肤病学 | 562篇 |
神经病学 | 1651篇 |
特种医学 | 358篇 |
外国民族医学 | 1篇 |
外科学 | 3081篇 |
综合类 | 72篇 |
一般理论 | 14篇 |
预防医学 | 1718篇 |
眼科学 | 664篇 |
药学 | 676篇 |
中国医学 | 16篇 |
肿瘤学 | 1318篇 |
出版年
2024年 | 113篇 |
2023年 | 862篇 |
2022年 | 370篇 |
2021年 | 731篇 |
2020年 | 733篇 |
2019年 | 563篇 |
2018年 | 1034篇 |
2017年 | 1032篇 |
2016年 | 950篇 |
2015年 | 883篇 |
2014年 | 1160篇 |
2013年 | 1182篇 |
2012年 | 1083篇 |
2011年 | 1038篇 |
2010年 | 851篇 |
2009年 | 977篇 |
2008年 | 775篇 |
2007年 | 711篇 |
2006年 | 684篇 |
2005年 | 560篇 |
2004年 | 474篇 |
2003年 | 402篇 |
2002年 | 348篇 |
2001年 | 148篇 |
2000年 | 94篇 |
1999年 | 124篇 |
1998年 | 148篇 |
1997年 | 113篇 |
1996年 | 76篇 |
1995年 | 80篇 |
1994年 | 62篇 |
1993年 | 42篇 |
1992年 | 72篇 |
1991年 | 58篇 |
1990年 | 50篇 |
1989年 | 40篇 |
1988年 | 34篇 |
1987年 | 30篇 |
1986年 | 33篇 |
1985年 | 26篇 |
1984年 | 15篇 |
1983年 | 23篇 |
1982年 | 17篇 |
1981年 | 17篇 |
1980年 | 15篇 |
1979年 | 16篇 |
1977年 | 11篇 |
1975年 | 11篇 |
1972年 | 12篇 |
1971年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
961.
962.
963.
Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Community‐Based Practice Registry
下载免费PDF全文
![点击此处可从《Journal of clinical hypertension (Greenwich, Conn.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Brent M. Egan MD Jiexiang Li PhD Douglas O. Fleming MPH Kellee White PhD Kenneth Connell MBBS PhD Robert A. Davis MS Angelo Sinopoli MD 《Journal of clinical hypertension (Greenwich, Conn.)》2016,18(7):663-671
Electronic health record data were analyzed to estimate the number of statin‐eligible adults with the 2013 American College of Cardiology/American Heart Association cholesterol guidelines not taking statin therapy and the impact of recommended statin therapy on 10‐year atherosclerotic cardiovascular disease (ASCVD10) events. Adults aged 21 to 80 years in an outpatient network with ≥1 clinic visit(s) from January 2011 to June 2014 with data to calculate ASCVD10 were eligible. Moderate‐intensity statin therapy was assumed to lower low‐density lipoprotein cholesterol by 30% and high‐intensity therapy was assumed to reduce low‐density lipoprotein cholesterol by 50%. ASCVD events were assumed to decline 22% for each 39 mg/dL decline in low‐density lipoprotein cholesterol. Among 411,768 adults, 260,434 (63.2%) were not taking statins and 103,478 (39.7%) were eligible for a statin, including 79,069 (76.4%) patients with hypertension. Estimated ASCVD10 events were 18,781 without and 13,328 with statin therapy, a 29.0% relative and 5.3% absolute risk reduction with a number needed to treat of 19. The 2013 cholesterol guidelines are a relatively efficient approach to reducing ASCVD in untreated, statin‐eligible adults who often have concomitant hypertension. 相似文献
964.
Lesley-Ann Sutton Viktor Ljungstr?m Larry Mansouri Emma Young Diego Cortese Veronika Navrkalova Jitka Malcikova Alice F. Muggen Martin Trbusek Panagiotis Panagiotidis Frederic Davi Chrysoula Belessi Anton W. Langerak Paolo Ghia Sarka Pospisilova Kostas Stamatopoulos Richard Rosenquist 《Haematologica》2015,100(3):370-376
Next-generation sequencing has revealed novel recurrent mutations in chronic lymphocytic leukemia, particularly in patients with aggressive disease. Here, we explored targeted re-sequencing as a novel strategy to assess the mutation status of genes with prognostic potential. To this end, we utilized HaloPlex targeted enrichment technology and designed a panel including nine genes: ATM, BIRC3, MYD88, NOTCH1, SF3B1 and TP53, which have been linked to the prognosis of chronic lymphocytic leukemia, and KLHL6, POT1 and XPO1, which are less characterized but were found to be recurrently mutated in various sequencing studies. A total of 188 chronic lymphocytic leukemia patients with poor prognostic features (unmutated IGHV, n=137; IGHV3-21 subset #2, n=51) were sequenced on the HiSeq 2000 and data were analyzed using well-established bioinformatics tools. Using a conservative cutoff of 10% for the mutant allele, we found that 114/180 (63%) patients carried at least one mutation, with mutations in ATM, BIRC3, NOTCH1, SF3B1 and TP53 accounting for 149/177 (84%) of all mutations. We selected 155 mutations for Sanger validation (variant allele frequency, 10–99%) and 93% (144/155) of mutations were confirmed; notably, all 11 discordant variants had a variant allele frequency between 11–27%, hence at the detection limit of conventional Sanger sequencing. Technical precision was assessed by repeating the entire HaloPlex procedure for 63 patients; concordance was found for 77/82 (94%) mutations. In summary, this study demonstrates that targeted next-generation sequencing is an accurate and reproducible technique potentially suitable for routine screening, eventually as a stand-alone test without the need for confirmation by Sanger sequencing. 相似文献
965.
Ioana Agache Cezmi A. Akdis Mubeccel Akdis Knut Brockow Tomas Chivato Stefano del Giacco Thomas Eiwegger Kilian Eyerich Ana Giménez-Arnau Jan Gutermuth Emma Guttman-Yassky Marcus Maurer Graham Ogg Peck Y. Ong Liam O’Mahony Jürgen Schwarze Amena Warner Thomas Werfel Oscar Palomares Marek Jutel 《Allergy》2021,76(4):988-1009
Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed. 相似文献
966.
Wendy F. Davidson Donald Y.M. Leung Lisa A. Beck Cecilia M. Berin Mark Boguniewicz William W. Busse Talal A. Chatila Raif S. Geha James E. Gern Emma Guttman-Yassky Alan D. Irvine Brian S. Kim Heidi H. Kong Gideon Lack Kari C. Nadeau Julie Schwaninger Angela Simpson Eric L. Simpson Marshall Plaut 《The Journal of allergy and clinical immunology》2019,143(3):894-913
967.
968.
Update and Mutational Analysis of SLC20A2: A Major Cause of Primary Familial Brain Calcification
下载免费PDF全文
![点击此处可从《Human mutation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Roberta R. Lemos Eliana M. Ramos Andrea Legati Gaël Nicolas Emma M. Jenkinson John H. Livingston Yanick J. Crow Dominique Campion Giovanni Coppola João R. M. Oliveira 《Human mutation》2015,36(5):489-495
Primary familial brain calcification (PFBC) is a heterogeneous neuropsychiatric disorder, with affected individuals presenting a wide variety of motor and cognitive impairments, such as migraine, parkinsonism, psychosis, dementia, and mood swings. Calcifications are usually symmetrical, bilateral, and found predominantly in the basal ganglia, thalamus, and cerebellum. So far, variants in three genes have been linked to PFBC: SLC20A2, PDGFRB, and PDGFB. Variants in SLC20A2 are responsible for most cases identified so far and, therefore, the present review is a comprehensive worldwide summary of all reported variants to date. SLC20A2 encodes an inorganic phosphate transporter, PiT‐2, widely expressed in various tissues, including brain, and is part of a major family of solute carrier membrane transporters. Fifty variants reported in 55 unrelated patients so far have been identified in families of diverse ethnicities and only few are recurrent. Various types of variants were detected (missense, nonsense, frameshift) including full or partial SLC20A2 deletions. The recently reported SLC20A2 knockout mouse will enhance our understanding of disease mechanism and allow for screening of therapeutic compounds. In the present review, we also discuss the implications of these recent exciting findings and consider the possibility of treatments based on manipulation of inorganic phosphate homeostasis. 相似文献
969.
Bronchiolar Remodeling in Adult Mice Following Neonatal Exposure to Hyperoxia: Relation to Growth
下载免费PDF全文
![点击此处可从《Anatomical record (Hoboken, N.J. : 2007)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Megan O'Reilly Philip M. Hansbro Jay C. Horvat Emma L. Beckett Richard Harding Foula Sozo 《Anatomical record (Hoboken, N.J. : 2007)》2014,297(4):758-769
Preterm infants who receive supplemental oxygen for prolonged periods are at increased risk of impaired lung function later in life. This suggests that neonatal hyperoxia induces persistent changes in small conducting airways (bronchioles). Although the effects of neonatal hyperoxia on alveolarization are well documented, little is known about its effects on developing bronchioles. We hypothesized that neonatal hyperoxia would remodel the bronchiolar walls, contributing to altered lung function in adulthood. We studied three groups of mice (C57BL/6J) to postnatal day 56 (P56; adulthood) when they either underwent lung function testing or necropsy for histological analysis of the bronchiolar wall. One group inhaled 65% O2 from birth until P7, after which they breathed room air; this group experienced growth restriction (HE+GR group). We also used a group in which hyperoxia‐induced GR was prevented by dam rotation (HE group). A control group inhaled room air from birth. At P56, the bronchiolar epithelium of HE mice contained fewer Clara cells and more ciliated cells, and the bronchiolar wall contained ~25% less collagen than controls; in HE+GR mice the bronchiolar walls had ~13% more collagen than controls. Male HE and HE+GR mice had significantly thicker bronchiolar epithelium than control males and altered lung function (HE males: greater dynamic compliance; HE+GR males: lower dynamic compliance). We conclude that neonatal hyperoxia remodels the bronchiolar wall and, in adult males, affects lung function, but effects are altered by concomitant growth restriction. Our findings may partly explain the reports of poor lung function in ex‐preterm children and adults. Anat Rec, 297:758–769, 2014. © 2014 Wiley Periodicals, Inc. 相似文献
970.